Wedbush Morning Call - May 15 2026 7:11AM

Research evidence excerpt

Wedbush Morning Call - May 15 2026 7:11AM

her studies in neurodegenerative diseases) may have been a reason for the study to miss the primary

endpoint. Therefore, we are optimistic that VY1706, which leverages VYGR's CNS penetrant capsid and has shown up to 64%

reduction in tau protein expression in key brain regions of non-human primates (NHPs), could produce potent and durable tau

suppression in AD patients to reduce cognitive decline after entering the clinic in 2H26.

BIIB080's Ph1b Show Promising Efficacy. Recall data from the Ph1b study (NCT03186989) showed time-dependent reduction

in tau accumulation from baseline that was correlated with BIIB080 exposure (Nat Med. 2023). Additionally, tau PET imaging

data showed reductions from baseline in brain neurofibrillary tangle across all brain regions assessed, although patients

also showed an increase from baseline in cerebral ventricular volume and a reduction from baseline in whole brain volume,

including subtle decreases in total hippocampal volume, at week 100 in the long-term extension (LTE) study (JAMA Neurol.

2023). Importantly, the recently published functional data showed a numerically smaller decline in cognitive, functional and

global measures favoring BIIB080 high-dose groups at both week 25 and week 37 (Nature Aging. 2026). Additionally, an

exploratory analysis of patients that received high doses throughout the MAD and LTE periods, using external controls with

similar baseline characteristics from the Ph2 TANGO study of anti-tau mAb gosuranemab from BIIB, also showed a numerical

difference on the same efficacy measures that favored BIIB080.

Preclinical Data Show Robust Tau Reduction by VY1706. The 3-month toxicology study data from NHPs, which were presented